Table 7_Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in breast cancer p

Fifty-six studies involving 16,539 patients were included in this systematic review and meta-analysis. It synthesizes pooled hazard ratios and odds ratios to examine the association between pretreatment neutrophil-to-lymphocyte ratio (NLR) and survival outcomes in breast cancer patients treated with neoadjuvant chemotherapy. The dataset, authored by Ziqian Zhao and last updated in May 2026, is available as a DOCX document under a CC-BY-4.0 license.

Use Cases

• Validate the prognostic value of neutrophil-to-lymphocyte ratio (NLR) based on pooled hazard ratios for overall survival.
• Assess the relationship between pretreatment NLR and pathologic complete response (pCR) rates based on synthesized odds ratios.
• Investigate heterogeneity in biomarker cutoffs and study designs across 56 included studies.
• Support the design of prospective clinical trials for biomarker validation based on the systematic review conclusions.

Strengths

• Analysis is based on 56 studies encompassing 16,539 patients, providing a substantial evidence base.
• Results include specific pooled hazard ratios (e.g., HR=1.89 for OS) and odds ratios (OR=0.50 for pCR) with confidence intervals.
• Findings were validated through sensitivity analyses restricted to multivariable-adjusted estimates.

Limitations

• The dataset is a 15.2 KB DOCX document; the underlying tabular data (e.g., study-level results) is not provided in a structured, machine-readable format.
• Substantial heterogeneity and inconsistent NLR cutoffs across studies are noted as limitations in the source document.
• Column-level documentation is absent; field semantics must be inferred from the text.

Provenance

Source

figshare, author Ziqian Zhao

Collection Method

Systematic review and meta-analysis of studies from PubMed, EMBASE, Web of Science, and the Cochrane Library.

Time Range

Studies published up to April 2026.

Freshness

Last updated 2026-05-29 04:52:33